$ENHAEnhanced Group Inc. Class A · Financial - Conglomerates · $221.3M
Street Buy · PT $5 (+1.9%)
$1.72
+1.2%
Event thread
Key events, in time order
13 items
EarningsBear
ENHA Q2 Revenue $17.7M Misses $24.6M Estimate, Net Loss $61.9M, Stock Down Over 20%
Revenue from inaugural Enhanced Games sponsorships fell short; losses widened as event investment continued
D1 -1.5% · +5d -5.3%
›2 waves of this story
2026-08-06 Company officially announces earnings date, market awaits results
2026-08-14 Revenue from inaugural Enhanced Games sponsorships fell short; losses widened as event investment continued
8-K filing
8-K: Item 2.02, Item 9.01
D1 -21.6% · +5d -12.2%
11 earlier events›
Earnings
Earnings report
D1 +11.6% · +5d -32.0%
CompanyBull
ENHA Expands Supplement Line to 33 International Markets
Today's announcement confirms availability in EU27, UK, Canada, etc., adding specific market details to the existing event.
D1 +4.5% · +5d -4.7%
›2 waves of this story
2026-07-30 Company announces international expansion of DTC supplement line to 33 markets
2026-07-30 Today's announcement confirms availability in EU27, UK, Canada, etc., adding specific market details to the existing event.
RegulationBull
FDA Advisory Committee Votes to Expand Peptide Compounding Pathway; ENHA Applauds
ENHA executives attended FDA meeting; company publicly supports expanded peptide compounding pathway
D1 -4.2% · +5d +33.3%
›6 waves of this story
2026-07-16 FDA's Pharmacy Compounding Advisory Committee to review seven peptides including BPC-157 and TB-500, potentially impacting ENHA's regulatory landscape
2026-07-17 Company confirms invitation to contribute to hearings, reinforcing its role in peptide-related discussions
2026-07-23 Hearings start today; CEO says ENHA will move quickly to offer peptides via medical platform if path forward, building on prior PCAC invitation.
2026-07-25 Advisory committee votes on remaining peptides; 6/7 total favorable for 503A Bulks List path
2026-07-27 FDA advisory committee landmark vote, ENHA commends, adding positive signal to formal rulemaking for PCAC heptapeptide
2026-07-28 ENHA executives attended FDA meeting; company publicly supports expanded peptide compounding pathway
2026-07-04 Event is one week away from material date, serving as a marketing milestone for ENHA's Thor Protocol and reinforcing the 2026 revenue guidance of $57M
2026-07-06 Doc covers ENHA from May 2025 announcement through inaugural Las Vegas event on May 24, 2026
8-K filing
8-K: Item 1.01, Item 1.02, Item 3.02, Item 5.07
D1 -3.6% · +5d +4.5%
Earnings
Earnings report
D1 -1.4% · +5d +53.0%
8-K filing
8-K: Item 1.01, Item 2.01, Item 3.01, Item 3.02
D1 +20.8% · +5d -50.8%
8-K filing
8-K: Item 5.07, Item 7.01, Item 8.01, Item 9.01
D1 +4.7% · +5d -34.4%
Earnings
Earnings report
D1 +4.7% · +5d -34.4%
8-K filing
8-K: Item 3.01, Item 7.01, Item 9.01
D1 +0.2% · +5d +8.5%
①
Bull vs bear
by direction · sourced
Bull0
None yet
Bear0
None yet
Community
AI synthesis + sources
⑩
Discussion
be the first
Be civil · your views are your own
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
Event thread
Key events, in time order
13 items
EarningsBear
ENHA Q2 Revenue $17.7M Misses $24.6M Estimate, Net Loss $61.9M, Stock Down Over 20%
Revenue from inaugural Enhanced Games sponsorships fell short; losses widened as event investment continued
D1 -1.5% · +5d -5.3%
›2 waves of this story
2026-08-06 Company officially announces earnings date, market awaits results
2026-08-14 Revenue from inaugural Enhanced Games sponsorships fell short; losses widened as event investment continued
8-K filing
8-K: Item 2.02, Item 9.01
D1 -21.6% · +5d -12.2%
Earnings
Earnings report
D1 +11.6% · +5d -32.0%
CompanyBull
ENHA Expands Supplement Line to 33 International Markets
Today's announcement confirms availability in EU27, UK, Canada, etc., adding specific market details to the existing event.
D1 +4.5% · +5d -4.7%
›2 waves of this story
2026-07-30 Company announces international expansion of DTC supplement line to 33 markets
2026-07-30 Today's announcement confirms availability in EU27, UK, Canada, etc., adding specific market details to the existing event.
RegulationBull
FDA Advisory Committee Votes to Expand Peptide Compounding Pathway; ENHA Applauds
ENHA executives attended FDA meeting; company publicly supports expanded peptide compounding pathway
D1 -4.2% · +5d +33.3%
›6 waves of this story
2026-07-16 FDA's Pharmacy Compounding Advisory Committee to review seven peptides including BPC-157 and TB-500, potentially impacting ENHA's regulatory landscape
2026-07-17 Company confirms invitation to contribute to hearings, reinforcing its role in peptide-related discussions
2026-07-23 Hearings start today; CEO says ENHA will move quickly to offer peptides via medical platform if path forward, building on prior PCAC invitation.
2026-07-25 Advisory committee votes on remaining peptides; 6/7 total favorable for 503A Bulks List path
2026-07-27 FDA advisory committee landmark vote, ENHA commends, adding positive signal to formal rulemaking for PCAC heptapeptide
2026-07-28 ENHA executives attended FDA meeting; company publicly supports expanded peptide compounding pathway
2026-07-04 Event is one week away from material date, serving as a marketing milestone for ENHA's Thor Protocol and reinforcing the 2026 revenue guidance of $57M
2026-07-06 Doc covers ENHA from May 2025 announcement through inaugural Las Vegas event on May 24, 2026
